- The stock was sold by three insiders within one month.
- The stock was not purchased by any insiders in the month of intensive selling.
- Two of these three insiders decreased their holdings by more than 10%.
Biocryst Pharmaceuticals Inc. is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include Peramivir, BCX4161, Forodesine and Ulodesine, among others.